Andrew Kondratowicz
Andrew Kondratowicz, PhD
Team Lead, BioAssay Development
Precision NanoSystems
Gemma Ryan
Gemma Ryan, PhD
Manager, Formulation Development
Precision NanoSystems
Daniela Salas
Daniela Salas, PhD
Senior Scientist, Analytical Development
Precision NanoSystems

Broadcast Date: 
  • Time: 

Nucleic acids (e.g., siRNA, mRNA and saRNA) can be designed and formulated to silence, express, and edit specific genes providing a flexible and powerful approach to preventing and treating diseases. The recent commercialization and widespread distribution of COVID-19 mRNA vaccines has exemplified the massive potential of this new class of genomic medicines and vaccines to effectively thwart emerging viral threats and treat a wide range of challenging diseases. Part of developing a successful mRNA therapeutic or vaccine is choosing a delivery mechanism that protects the nucleic acids on the way to their target tissue. Encapsulating mRNA in lipid nanoparticles has proven to be one of the best vehicles for overcoming extracellular and intracellular barriers and safely delivering the treatment. Several mRNA-LNP formulations that target things like viral infections and cancers are being evaluated clinically.

In this webinar, three experts will discuss how Precision Nanosystems’ modular microfluidic platform technologies and analytics can help scientists successfully design, develop, test, and scale-up promising mRNA-LNP vaccines and therapeutics from concept to clinic. They will provide an overview of Precision NanoSystem’s Biopharma Services, and share examples from internal R&D work that demonstrate the versatility of the genetic medicine toolbox for rapidly developing RNA-LNP vaccines. You’ll also learn about Precision NanoSystem’s BioAssay services and the capabilities that are available to facilitate and accelerate drug development projects.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelists.

Produced with support from:

Precision NanoSystems logo